Literature DB >> 21467232

Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.

Mary Ann Comunale1, Mengjun Wang, Lucy Rodemich-Betesh, Julie Hafner, Anne Lamontagne, Andrew Klein, Jorge Marrero, Adrian M Di Bisceglie, Robert Gish, Timothy Block, Anand Mehta.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the occurrence of HCC has more than doubled in the United States in the past decade. Early detection is considered key to reducing the mortality of HCC.
METHODS: Using two-dimensional gel electrophoresis and high-performance liquid chromatography we have analyzed the glycosylation of Apo-J from healthy controls, patients with liver cirrhosis, or those with HCC.
RESULTS: Apo-J in the serum from patients with HCC had decreased levels of (β-1,4) triantennary N-linked glycan compared with the healthy controls or patients with liver cirrhosis. We analyzed this change in an independent cohort of 76 patients with HCC, 32 with cirrhosis, and 43 infected with hepatitis C virus using the Datura stramonium lectin (DSL), which binds to (β-1,4) triantennary N-linked glycan. The level of DSL-reactive Apo-J allowed us to differentiate HCC from cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.852. When Apo-J was combined with other serum biomarkers such as α-fetoprotein (AFP) and fucosylated kininogen by using a multivariate logistic regression model, the AUROC increased to 0.944, a value much greater than that observed with AFP alone (AUROC of 0.765).
CONCLUSIONS: The glycosylation of Apo-J is a useful marker when used alone or in combination with outer makers for the early detection of HCC. IMPACT: The potential use of a combination of AFP, DSL-reactive Apo-J, and fucosylated kininogen as a biomarker of HCC would have great value in the management of patients with liver disease. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467232      PMCID: PMC3111882          DOI: 10.1158/1055-9965.EPI-10-1047

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  27 in total

Review 1.  Glycoproteins: rapid sequencing technology for N-linked and GPI anchor glycans.

Authors:  P M Rudd; T S Mattu; N Zitzmann; A Mehta; C Colominas; E Hart; G Opdenakker; R A Dwek
Journal:  Biotechnol Genet Eng Rev       Date:  1999

2.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

3.  Glycosyltransferase assays using pyridylaminated acceptors: N-acetylglucosaminyltransferase III, IV, and V.

Authors:  N Taniguchi; A Nishikawa; S Fujii; J G Gu
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

4.  Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.

Authors:  Yi Wang; Yan-Hui Liu; Shi-Juan Mai; Long-Jun He; Yi-Ji Liao; Hai-Xia Deng; Xin-Yuan Guan; Yi-Xin Zeng; Hsiang-Fu Kung; Dan Xie
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

5.  Alpha-1 fetoglobulin in the diagnosis of human hepatoma.

Authors:  M E Alpert; J Uriel; B de Nechaud
Journal:  N Engl J Med       Date:  1968-05-02       Impact factor: 91.245

6.  Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B.

Authors:  A M Di Bisceglie; J H Hoofnagle
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

Review 7.  Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection.

Authors:  A M Di Bisceglie
Journal:  Med Clin North Am       Date:  1989-07       Impact factor: 5.456

8.  Risk factors for hepatocellular carcinoma in patients with cirrhosis.

Authors:  Steedman A Sarbah; Terry Gramlich; Abraham Younoszai; Pat Osmack; Marlene Goormastic; Leonard Grosso; James N Cooper; Adrian Di Bisceglie; Russell Seneca; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 9.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

10.  Serum alpha-fetoprotein: diagnostic significance in liver disease.

Authors:  E Ruoslahti; M Salaspuro; H Pihko; L Andersson; M Seppälä
Journal:  Br Med J       Date:  1974-06-08
View more
  23 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Role of secretory clusterin in hepatocarcinogenesis.

Authors:  Min Yao; Miao Fang; Wenjie Zheng; Zhizhen Dong; Dengfu Yao
Journal:  Transl Gastroenterol Hepatol       Date:  2018-08-01

Review 3.  High-sensitivity analytical approaches for the structural characterization of glycoproteins.

Authors:  William R Alley; Benjamin F Mann; Milos V Novotny
Journal:  Chem Rev       Date:  2013-03-27       Impact factor: 60.622

4.  Development of recombinant Aleuria aurantia lectins with altered binding specificities to fucosylated glycans.

Authors:  Patrick R Romano; Andrew Mackay; Minh Vong; Johann DeSa; Anne Lamontagne; Mary Ann Comunale; Julie Hafner; Timothy Block; Ryszard Lec; Anand Mehta
Journal:  Biochem Biophys Res Commun       Date:  2011-09-14       Impact factor: 3.575

5.  Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.

Authors:  Peng Xiu; Zongzhen Xu; Feng Liu; Ziqiang Li; Tao Li; Fang Zou; Xueying Sun; Jie Li
Journal:  Dig Dis Sci       Date:  2014-03-27       Impact factor: 3.199

6.  Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.

Authors:  Lucy Betesh; Mary Ann Comunale; Mengjun Wang; Hongyan Liang; Julie Hafner; Aykan Karabudak; Nasra H Giama; Catherine D Moser; Eiji Miyoshi; Lewis R Roberts; Timothy M Block; Anand Mehta
Journal:  Proteomics Clin Appl       Date:  2017-07-10       Impact factor: 3.494

7.  Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma.

Authors:  Mengjun Wang; Jiabin Shen; Harmin Herrera; Amit Singal; Charles Swindell; Lu Renquan; Anand Mehta
Journal:  J Immunol Methods       Date:  2018-08-23       Impact factor: 2.303

8.  Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.

Authors:  Fateme Tousi; Jonathan Bones; Othon Iliopoulos; William S Hancock; Marina Hincapie
Journal:  J Chromatogr A       Date:  2012-07-28       Impact factor: 4.759

9.  Development and application of a novel recombinant Aleuria aurantia lectin with enhanced core fucose binding for identification of glycoprotein biomarkers of hepatocellular carcinoma.

Authors:  Pamela Norton; Mary Ann Comunale; Harmin Herrera; Mengjun Wang; Josef Houser; Michaela Wimmerova; Patrick R Romano; Anand Mehta
Journal:  Proteomics       Date:  2016-11-28       Impact factor: 3.984

Review 10.  Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.

Authors:  Peng Xiu; Xiao-Feng Dong; Xin-Ping Li; Jie Li
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.